EGFR and hepatocellular carcinoma: Cetuximab and panitumumab failed to inhibit the RAS/MAPK pathway in resistant cell lines (MDA-MB-231 and HCC-1937), whereas they reduced EGFR and ERK phosphorylation in sensitive cell lines (MDA-MB-468 and SUM-1315).